Table 11 |
||||
|
Regression Analyses of Changes in Autism Severity vs. Urinary Metal Excretion (after 9th dose of DMSA in Phase 1) and Changes in Glutathione (Dglut). |
||||
|
Adjusted R2 |
P-value |
Equation |
Most significant variables |
|
|
|
||||
|
Change in PDD-BI (n = 20) |
0.75 |
0.0006 |
10.25 -2.48Pb9 +0.169Sn9 +113.5Tl9 -119.1Sb9 - 1.199As9 +0.726Al9 - 0.0608DGlut |
Tl9**, As9**, DGlut**, Pb9*, Sb9* |
|
Change in ATEC (n = 20) |
0.44 |
0.006 |
9.41 -0.663Pb9 -8.80Hg9- 0.352As9 |
Hg9**, As9* |
|
Change in SAS (n = 18) |
0.57 |
0.002 |
-1.01 +0.0985Pb9- -0.00169DGlut |
Tl9**, Pb9*, DGlut* |
|
Change in ADOS (comm.. + social) (n = 20) |
0.28 |
0.02 |
-1.91+00.0472As9 - 0.0877Al9 |
As9*, Al9* |
|
|
||||
|
This is the same analysis as Table 10, except it is for the 7-round group only, resulting in much better regression fit and much greater significance in all cases. This demonstrates that the changes in the 7-round group are much better predicted by their excretion of heavy metals and change in glutathione. |
||||
|
Adams et al. BMC Clinical Pharmacology 2009 9:17 doi:10.1186/1472-6904-9-17 |
||||
